Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals Inc (NQ: DAWN )

13.60 -0.05 (-0.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 764,355
Open 13.79
Bid (Size) 13.30 (1)
Ask (Size) 13.60 (2)
Prev. Close 13.65
Today's Range 13.26 - 13.79
52wk Range 6.380 - 28.35
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
Via FinancialNewsMedia
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-32.84%
-32.84%
1 Month
-4.29%
-4.29%
3 Month
-27.43%
-27.43%
6 Month
-37.44%
-37.44%
1 Year
+103.90%
+103.90%

More News

Read More
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
Via FinancialNewsMedia
Exposures Product Safety
7 Analysts Have This to Say About Day One Biopharmaceutical
Via Benzinga
What 5 Analyst Ratings Have To Say About Day One Biopharmaceutical
Via Benzinga
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Analyst Expectations for Day One Biopharmaceutical's Future
Via Benzinga
What 8 Analyst Ratings Have To Say About Day One Biopharmaceutical
Via Benzinga
Where Day One Biopharmaceutical Stands With Analysts
Via Benzinga
What 7 Analyst Ratings Have To Say About Day One Biopharmaceutical
Via Benzinga
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Lam Research, D.R. Horton, Las Vegas Sands And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Participate in the Cowen 43rd Annual Health Care Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
Day One Biopharmaceuticals Shares Jump As Pediatric Brain Cancer Candidate Shows Encouraging Responses
Via Benzinga
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.